These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33082443)

  • 1. Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort.
    Pérez-Cordón A; Monté-Rubio G; Sanabria A; Rodriguez-Gomez O; Valero S; Abdelnour C; Marquié M; Espinosa A; Ortega G; Hernandez I; Rosende-Roca M; Vargas L; Mauleón A; Gil S; Tartari JP; Lomeña F; Campos F; Vivas A; Gomez-Chiari M; Benaque A; Ruiz A; Tárraga L; Boada M; Alegret M;
    Sci Rep; 2020 Oct; 10(1):17721. PubMed ID: 33082443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).
    de Rojas I; Romero J; Rodríguez-Gomez O; Pesini P; Sanabria A; Pérez-Cordon A; Abdelnour C; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Alegret M; Espinosa A; Ortega G; Gil S; Guitart M; Gailhajanet A; Santos-Santos MA; Moreno-Grau S; Sotolongo-Grau O; Ruiz S; Montrreal L; Martín E; Pelejà E; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MA; Giménez J; Pérez-Grijalba V; Marquié GM; Monté-Rubio G; Valero S; Orellana A; Tárraga L; Sarasa M; Ruiz A; Boada M;
    Alzheimers Res Ther; 2018 Nov; 10(1):119. PubMed ID: 30497535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity.
    Ali DG; Bahrani AA; Barber JM; El Khouli RH; Gold BT; Harp JP; Jiang Y; Wilcock DM; Jicha GA
    J Alzheimers Dis; 2022; 88(3):1127-1135. PubMed ID: 35754276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.
    Marquié M; Valero S; Castilla-Marti M; Martínez J; Rodríguez-Gómez O; Sanabria Á; Tartari JP; Monté-Rubio GC; Sotolongo-Grau O; Alegret M; Pérez-Cordón A; Roberto N; de Rojas I; Moreno-Grau S; Montrreal L; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Abdelnour C; Gil S; Esteban-De Antonio E; Espinosa A; Ortega G; Lomeña F; Pavia J; Vivas A; Tejero MÁ; Gómez-Chiari M; Simó R; Ciudin A; Hernández C; Orellana A; Benaque A; Ruiz A; Tárraga L; Boada M;
    Alzheimers Res Ther; 2020 Mar; 12(1):37. PubMed ID: 32234080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of white matter hyperintensities and Aβ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort.
    Ortega G; Espinosa A; Alegret M; Monté-Rubio GC; Sotolongo-Grau O; Sanabria A; Tartari JP; Rodríguez-Gómez O; Marquié M; Vivas A; Gómez-Chiari M; Alarcón-Martín E; Pérez-Cordón A; Roberto N; Hernández I; Rosende-Roca M; Vargas L; Mauleón A; Abdelnour C; Esteban De Antonio E; López-Cuevas R; Alonso-Lana S; Moreno-Grau S; de Rojas I; Orellana A; Montrreal L; Tárraga L; Ruiz A; Boada M; Valero S;
    Alzheimers Res Ther; 2021 Aug; 13(1):141. PubMed ID: 34404456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline.
    Sanabria A; Alegret M; Rodriguez-Gomez O; Valero S; Sotolongo-Grau O; Monté-Rubio G; Abdelnour C; Espinosa A; Ortega G; Perez-Cordon A; Gailhajanet A; Hernandez I; Rosende-Roca M; Vargas L; Mauleon A; Sanchez D; Martin E; Rentz DM; Lomeña F; Ruiz A; Tarraga L; Boada M;
    Sci Rep; 2018 Feb; 8(1):3828. PubMed ID: 29491481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?
    Funaki K; Nakajima S; Noda Y; Wake T; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M; Tabuchi H
    Psychogeriatrics; 2019 Jul; 19(4):325-332. PubMed ID: 30688000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
    Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
    Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtle Cognitive Deficits Are Associated with Amyloid-β Positivity, but Not Severity of Self-Reported Decline: Results from the CoSCo Study.
    Ryu SY; Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW
    Dement Geriatr Cogn Disord; 2022; 51(2):159-167. PubMed ID: 35381591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.